Safety study of an experimental vaccine in healthy adults
Treatments studied
This early-phase study tests whether a new vaccine called V118E is safe and well-tolerated in healthy people. It is for adults who are in good health and have not recently had a pneumococcal infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be in good health overall.
- You must not have had a pneumococcal infection (a serious lung or blood infection caused by bacteria) in the last 3 years.
- You must not have a history of major health problems such as heart disease, lung disease, kidney disease, liver disease, stomach issues, immune disorders, stroke, or seizures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new vaccine called V132 in healthy older people. It aims to see if the vaccine is safe and how the body responds to it.
This study tests whether a new pneumococcal vaccine (which protects against a serious bacterial infection) is safe in healthy 2-month-old infants. Researchers will watch for side effects and help protect future babies from pneumococcal disease.
This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.
This study tests a new pneumococcal vaccine (PCV15) to see how well it protects against carrying the bacteria that can cause pneumonia. Healthy adults aged 18–50 who have not had a pneumococcal vaccine in the last 5 years may join.
This study tests an investigational vaccine that may protect infants against infections caused by a bacteria called Streptococcus pneumoniae, which can cause pneumonia and other serious illnesses. The vaccine is given to healthy babies around 2 months old, and the study will see how well it works and how safe it is.
This trial tests a new vaccine called V118C to protect children against pneumococcal disease. It is for two age groups: toddlers aged 12-15 months who already had 3 doses of a standard pneumococcal vaccine, and babies about 2 months old who have not had any pneumococcal vaccine yet.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.